mRNA vaccines continue to show major promise.
In a small Phase 1 trial led by Dr. Balachandran, some patients with pancreatic cancer (one of the deadliest cancers) reached 6-year survival.
This is why sustained investment in science & research matters.
tinyurl.com/f4n4anhk
Posts by Alejandro Ibáñez-Costa
Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours in Endocrine Oncology Authors: Katharina Wang et al. Open Access. Figure 1. (A) 18F-SiTATE uptake assay using BON-1 SSTR2 cells after treatment with either paltusotine or octreotide. Cellular uptake was measured after (B) 30 min, (C) 120 min and (D) 240 min. DOTATATE acetate was used as the blocked control. The data are depicted as mean ± SD of four duplicate experiments. Molar concentrations: 100× (7.3–25.4 nM), 1,000× (73–254 nM), 2,000× (146–508 nM). Significantly lower radioligand uptake compared to the unblocked control *P < 0.05, **P < 0.01, ***P < 0.001. Endocrine Oncology 5, 1; 10.1530/EO-25-0041 Published by Bioscientifica. Society of Endocrinology.
New research by K Wang et al. suggest that paltusotine, a novel somatostatin analogue, could be continued during peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastro-enteropancreatic neuroendocrine tumours (GEP-NETs).
🔗 Explore the findings: doi.org/10.1530/EO-25-0041
Participando en el Evento de Celebración y Entrega de la 10ª Edición de las Becas Carmen Delgado/Miguel Pérez-Mateo a la Investigación Contra el Cáncer de Páncreas que organizan ACANPAN AESPANC y AEG
Escuchando la defensa de la investigacion por parte de Cristina Sandin y @evaortegapaino.bsky.social
En la 1ª mesa, panorámica de proyectos orientados al tratamiento del cáncer de páncreas, el Dr Alejandro Ibáñez Costa @avpr1b.bsky.social investigador GC08 @imibic.bsky.social @uco.es presenta el proyecto dirigido al desarrollo de vacunas de ARN basadas en splicing para el tratamiento personalizado
A day of scientific & personal JOY 🤩 for the H&C team!!
Dr Trinidad Moreno-Montilla presented her thesis, directed by Drs Alejandro Ibáñez-Costa + Sergio Pedraza-Arévalo Hormones&Cancer Group @imibic.bsky.social @uco.es
🔝Congratulations 🎊Trini 🙌🏼🦝 on your new PhD 👩🏻🎓 degree!
🔺👏🏼👏🏼Alejandro and Sergio!
A brilliant 💫 achievement wrapped by a great and lively presentation 🖥️ and discussion ✒️🖋️with the thesis committee
Thank you so much to this expert 🙌🏼🙌🏼 jury
Drs. Manuel Tena-Sempere👨🏻🎓
Julie Earl 👩🏻🎓&
Vincenzo Corbo 👨🏻🎓📺
for your valuable and insightful questions and suggestions
🙏🏼🙏🏼
1/20
El hígado acaba más estresado que tu amiga buscando entradas para #BadBunny🐰 si le das mucha caña...
Años de comida basura 🍟 = inflamación, daño celular y cáncer.
Te lo cuento en mi #HiloTesis 👇
@crueuniversidades.bsky.social @filarramendi.bsky.social @uco.es @cordobaciencia.bsky.social
"Single-molecule multimodal timing of in vivo mRNA synthesis" a collaboration with Rippei Hayashi's lab, work led by AJ Sethi #RNA #pre-mRNA #splicing #RNAprocessing #m6A #polyadenylation
www.biorxiv.org/content/10.1...
Excited to share our preprint on the molecular architecture of heterochromatin in human cells 🧬🔬w/ @jpkreysing.bsky.social, @johannesbetz.bsky.social,
@marinalusic.bsky.social, Turoňová lab, @hummerlab.bsky.social @becklab.bsky.social @mpibp.bsky.social
🔗 Preprint here tinyurl.com/3a74uanv
Congratulations to our pipette challenge winners at #ENETS2025 👏
Thank you to everyone that came by the booth and took part🤝 Until next time ✨
What if one variant can cause splicing outliers transcriptome-wide? In our preprint, we show how examining transcriptome-wide patterns of splicing outliers can both diagnose individuals with rare spliceopathies and uncover novel disease-gene relationships! (www.medrxiv.org/content/10.1...)
Ignacio Ruz-Caracuel et al. summarise current knowledge of cancer stem cells (CSCs) in #neuroendocrine #neoplasms and highlight the importance of understanding the role of CSCs in the biology of these rare tumors. Read it here 👉 https://buff.ly/40k6Tle
Buscamos personas altamente motivadas con la posibilidad de unirse al Grupo Hormonas y Cáncer, en el IMIBIC / Universidad de Córdoba, mediante la solicitud de un contrato Juan de la Cierva. #JuandelaCierva #IMIBIC #UCO #postdoc